Growth Factor News and Research

RSS

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).

29 Sep 2012

CSL develops new drug candidate against type 2 diabetes

CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease.

27 Sep 2012

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's

A team of neuroscientists and chemists from the U.S. and China today publish research suggesting that a class of currently used anti-cancer drugs as well as several previously untested synthetic compounds show effectiveness in reversing memory loss in two animal models of Alzheimer's disease.

25 Sep 2012

Conceptually novel mechanism for biological regulation of cell suicide

Death plays a big role in keeping things alive. Consider the tightly orchestrated suicide of cells--a phenomenon essential to everything from shaping an embryo to keeping it free of cancer later in life. When cells refuse to die, and instead multiply uncontrollably, they become what we call tumors. An intricate circuitry of biochemical reactions inside cells coordinates their self-sacrifice. Tracing that circuitry is, naturally, an important part of cancer research.

24 Sep 2012

Most basal-like breast and ovarian tumors have similar genetic origins

The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.

24 Sep 2012

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF).

24 Sep 2012

Scripps Florida scientist receives two grants to focus on sulfenylation

A scientist from the Florida campus of The Scripps Research Institute has been awarded a pair of grants totaling $2.8 million from the National Institute of General Medical Sciences of the National Institutes of Health, and from TargAnox, a Massachusetts-based biotechnology firm.

18 Sep 2012

PARP inhibitors may be novel treatment strategy in women with HER2-positive breast cancers

Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive breast cancers, according to the results of a study published in Cancer Research, a journal of the American Association for Cancer Research.

17 Sep 2012

Brandeis University biology professor receives NIH Director's New Innovator award

Chances are you didn't spend much time this morning getting your shoes on or thinking about which route you would take to work. But for people suffering with debilitating diseases such as ALS (Lou Gehrig's disease) or Alzheimer's, such simple functions -- and even activities like breathing and eating -- can be a struggle.

15 Sep 2012

U.K. scientists develop new test to catch drugs-cheats in sport

Scientists from three UK universities have developed a new test to catch drugs-cheats in sport.

15 Sep 2012

Gefitinib shows promise in Chinese lung cancer patients

Gefitinib improves progression-free survival, overall response, and health-related quality of life over carboplatin/paclitaxel for first-line advanced non-small-cell lung cancer treatment, a study indicates.

13 Sep 2012

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance of breast cancer to a well-regarded and widely used cancer therapy.

12 Sep 2012

KRAS gene mutation recruits second player to trigger pancreatic cancer

More than a cancer-causing gene is needed to trigger pancreatic cancer, a study led by Mayo Clinic has found. A second factor creates a "perfect storm" that allows tumors to form, the researchers say. The study, published in the Sept. 10 issue of Cancer Cell, overturns the current belief that a mutation in the KRAS oncogene is enough to initiate pancreatic cancer and unrestrained cell growth.

11 Sep 2012

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease.

11 Sep 2012

Two different genetic mutations cooperate to induce adrenal cancer

Two different genetic mutations cooperate to induce adrenal cancer, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center and University of Sao Paulo in Brazil.

11 Sep 2012

HIF-1 activity directly responsible for spread of breast cancer to lymph vessels

The invasion of cancer cells into the lymph vessels that connect the breast to surrounding lymph nodes is the first step leading to the metastasis, or spread, of cancer throughout the body. Metastasis is the primary cause of breast cancer deaths. Surprisingly little is known about the control of this process and how it might be interrupted to prolong the lives of women with breast cancer.

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

New molecular pathway that leads to preeclampsia identified

Preeclampsia is one of the most dangerous conditions for the expectant mother and the unborn child and is characterized by elevated blood pressure and protein in the urine in the last trimester of pregnancy.

10 Sep 2012

Skin, immune system play an important role in regulating sodium balance and hypertension

High blood pressure is responsible for many cardiovascular diseases that are the leading cause of death in industrialized countries. High salt intake has long been considered a risk factor, but not every type of high blood pressure is associated with high salt intake. This has puzzled scientists for a long time. However, new findings by Professor Jens Titze (Vanderbilt University, Nashville, Tennessee, USA and the University of Erlangen) now point to previously unknown mechanisms.

10 Sep 2012

Growth Factor News and Research

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

CSL develops new drug candidate against type 2 diabetes

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's

Conceptually novel mechanism for biological regulation of cell suicide

Most basal-like breast and ovarian tumors have similar genetic origins

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Scripps Florida scientist receives two grants to focus on sulfenylation

PARP inhibitors may be novel treatment strategy in women with HER2-positive breast cancers

Brandeis University biology professor receives NIH Director's New Innovator award

U.K. scientists develop new test to catch drugs-cheats in sport

Gefitinib shows promise in Chinese lung cancer patients

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

KRAS gene mutation recruits second player to trigger pancreatic cancer

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Two different genetic mutations cooperate to induce adrenal cancer

HIF-1 activity directly responsible for spread of breast cancer to lymph vessels

Combining two drugs may offer new and potent punch against cancer and other diseases

New molecular pathway that leads to preeclampsia identified

Skin, immune system play an important role in regulating sodium balance and hypertension

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News